• About
  • Masthead
  • License Content
  • Advertise
  • Press Releases
  • Newsroom
  • RSS/Email List
  • 2MM Podcast
  • Write for us
  • Contact Us
2 Minute Medicine
No Result
View All Result

No products in the cart.

Sign in
SUBSCRIBE
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
2 Minute Medicine
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
Sign in
SUBSCRIBE
2 Minute Medicine
Sign in
Subscribe
2 Minute MedicineFree on Google PlayGet
✦EvidencePulse™by 2 Minute Medicine3 reportsYou askedtop stroke trials 2026Synthesizing medical evidence...Top 2026 stroke trial results:OCEANIC — ischemic stroke: 6.2% vs 8.4%OPTION* — mRS 0–1: 43.6% vs 34.2%ORIENTAL* — mRS 0–2: 58.6% vs 46.6%*Higher sICH in intervention armsParticipants randomizedNOCEANIC12,327OPTION570ORIENTAL564Ask about guidelines or landmark trials...↑Try EvidencePulse™Ask the evidence. Get the signal.Try it now →
Home All Specialties Chronic Disease

Oral HIV preexposure prophylaxis limits willingness to pay for long-acting injectable prophylaxis

byDavid XiangandHarsh Shah
February 14, 2022
in Chronic Disease, Infectious Disease, Public Health
Reading Time: 3 mins read
Prescription medicines collage: a mortar and pestle, a blister pack of white tablets, teal capsules and a glass beaker
Share on FacebookShare on TwitterShare on LinkedIn

1. Compared with generic oral emtricitabine-tenofovir disoproxil fumarate (F/TDF), long-acting injectable cabotegravir (CAB-LA) increased life expectancy by 28,000 QALYs.

2. In PrEP-eligible populations, CAB-LA could achieve incremental cost-effectiveness ratios of at most $100,000 per QALY compared to generic F/TDF.

Evidence Rating Level: 2 (Good)

Study Rundown: The HIV Prevention Trials Network 083 trial demonstrated superior effectiveness for HIV pre-exposure prophylaxis when using CAB-LA compared to daily oral F/TDF for men who have sex with men and transgender women. However, with various pricing models, including generic and branded F/TDF, there is a gap in knowledge as to understanding how much society should be willing to pay for the improved effectiveness of CAB-LA over both branded and generic F/TDF options. This study found that the incremental clinical benefits of CAB-LA would not justify a large price difference compared with F/TDF, especially the generic brand which is substantially less expensive than the branded version. This study was limited by uncertainties of future HIV transmissions and the lack of data to incorporate potential changes in quality of life while receiving oral or long-acting PrEP. Nevertheless, these study’s findings are significant, as they demonstrate that though CAB-LA may offer superior clinical benefits, with the presence of highly effective and affordable oral PrEP alternatives, this limits the additional price that society should be willing to pay for CAB-LA.

Click to read the study in the Annals of Internal Medicine

Relevant Reading: Determining the Most Appropriate Use of Available Regimens for HIV Preexposure Prophylaxis

RELATED REPORTS

Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy

Maternal engagement in HIV care associated with pediatric viral suppression

FDA approvedFor HIV: Idvynso (doravirine and islatravir), Apr 20, 2026→

In-Depth [cost-effectiveness analysis]: This cost-effectiveness analysis utilized the cost-effectiveness of preventing AIDS complications model, a validated state-transition microsimulation model of HIV prevention and treatment. Persons with HIV incidences were included in the study whereas persons who discontinued participation in a PrEP program were excluded from the study. Estimated HIV incidence was as follows: 5.32, 1.33, and 0.26 per 100 person-years for off PrEP, generic F/TDF and branded F/TDF, and CAB-LA, respectively. Annual base-case drug costs were as follows: $360 and $16 800 for generic F/TDF and branded F/TAF. The primary outcome measured was quality-adjusted life-years (QALYs), costs (2020 US dollars), incremental cost-effectiveness ratios (ICERs), and maximum price premium for CAB-LA versus F/TDF. Outcomes in the primary analysis were assessed via sensitivity and scenario analyses. In the case-based analysis, CAB-LA increased life expectancy by 28,000 QALYs compared to generic or branded F/TDF. At ten years, CAB-LA had an ICER of at most $100,000 per QALY compared to generic F/TDF at a maximum price premium of $3700 per year over generic F/TDF (if CAB-LA price <$4100 a year). In the sensitivity analysis, CABA-LA could achieve an ICER of $100 000 per QALY versus generic F/TDF at a maximum price premium of $1100 per year over generic F/TDF. Using simulation models, CAB-LA would only provide good value for money if its annual price was less than $3000 to $6600 higher than generic F/TDF. Therefore, CAB-LA should be priced to compete with generic PrEP, not branded PrEP. Overall, this study demonstrates that though CAB-LA may be clinically superior, the return on investment may not justify a switch from low-priced, well-tolerated, generic, oral alternatives, depending on how CAB-LA is priced.

Image: PD

©2022 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

 

Tags: branded drugsCabotegravircost-effectiveemtricitabinegeneric drugsHIVpre-exposure prophylaxis (PrEPtenofovir disoproxil fumarate
Previous Post

Venous thromboembolism rates in hospitalized children continue to rise

Next Post

Immediate drainage of infected necrotizing pancreatitis shows no benefit over postponed drainage

RelatedReports

A circular calendar divided into sections, with a blue pill resting on one section and representations of HIV particles surrounding it, symbolizing HIV treatment adherence.
Chronic Disease

Use of long-acting broadly neutralizing antibodies may delay human immunodeficiency virus (HIV) rebound following discontinuation of antiretroviral therapy

September 24, 2026
HIV care collage: a smiling middle-aged man with an awareness ribbon pinned to his shirt beside a sprig of olive leaves
Infectious Disease

Maternal engagement in HIV care associated with pediatric viral suppression

August 28, 2026
Hybrid minimally invasive esophagectomy associated with lower complication rates compared to open esophagectomy
Chronic Disease

Active surveillance is cost-effective compared with standard surgery among esophageal cancer patients with complete clinical response after neoadjuvant chemoradiotherapy

August 6, 2026
Prescription medicines collage: a mortar and pestle, a blister pack of white tablets, teal capsules and a glass beaker
Pharma

Global medicine supply chains face mounting pressure amid Strait of Hormuz disruptions

May 5, 2026
Next Post

Immediate drainage of infected necrotizing pancreatitis shows no benefit over postponed drainage

Cervical cancer collage: a teal and white awareness ribbon, a vaccine vial, a glass slide, white lilies and a clinic gown

Cemiplimab treatment of recurrent cervical cancer is associated with longer overall survival

Absence of coronary plaque among symptomatic patients with high low-density lipoprotein cholesterol levels associated with low risk of atherosclerotic cardiovascular disease events

✦ EvidencePulse™ by 2 Minute Medicine 3 reports You asked top stroke trials 2026 Synthesizing medical evidence... Top 2026 stroke trial results: OCEANIC — ischemic stroke: 6.2% vs 8.4% OPTION* — mRS 0–1: 43.6% vs 34.2% ORIENTAL* — mRS 0–2: 58.6% vs 46.6% *Higher sICH in intervention arms Participants randomizedN OCEANIC 12,327 OPTION 570 ORIENTAL 564 Ask about guidelines or landmark trials... Try EvidencePulse™ Get the signal. Try it now → Physician-trained medical AI by 2 Minute Medicine

2MM+ All Access

Full details →
$4.99 /month

3-day free trial · cancel anytime

  • ✓100+ physician-written reports
  • ✓EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • AI Model Shows Promise in Predicting PTSD Risk Following Trauma
  • 2 Minute Medicine Rewind November 16, 2026
  • ERX1000 plus semaglutide increased weight loss and metabolic measures in diet-induced obese mice
License Content
Terms of Use | Disclaimer
Cookie Policy

Get the app

Read 2 Minute Medicine on iPhone, iPad and Android.

Download on the App StoreGet it on Google Play
QR code for www.2minutemedicine.com/app
On a computer? Scan this with your phone’s camera.
2MM+ All Access Full details →

The medical literature, distilled daily.

Monthly plan selected: $4.99 /month.

$4.99/month

3-day free trial · cancel anytime

Start 3-day free trial

Then $4.99/month. Manage renewal in your account.

Yearly plan selected: $49.90 /year.

$49.90/year

2 months free

Start 3-day free trial

Then $49.90/year.

Membership benefits

  • ✓100+ new physician-written study summaries monthly, 12,000+ searchable
  • ✓AI EvidencePulse™ + HypeCheck™
  • ✓Ad-free reading + newsletters
  • ✓FDA drug approvals + clinical calculators

Already a member? Sign in

  • Get the app
  • About
  • Specialties
    • All Specialties, All Recent Reports
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Pharma
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
    • Rewinds
    • The Scan
  • EvidencePulse™
  • HypeCheck™
  • AI News
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Tools
    • NPI Registry Lookup
    • RVU Search
    • Physician Pay by Specialty
    • ICD-10 Code Lookup
    • FDA Drug Approvals
    • Drug Safety for Breastfeeding/Pregnancy
    • Clinical Guidelines
    • Medical Calculators
    • ECG Reference
      • QTc Calculator
      • Sgarbossa Criteria
      • ECG Axis Calculator
      • AV Block Helper
  • Rankings
    • Medical School Rankings
    • Residency Rankings
  • Partners
    • License Content
    • Advertise with Us
No Result
View All Result

© 2026 2 Minute Medicine, Inc. - Physician-written medical news.